Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus EDROPHONIUM CHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus EDROPHONIUM CHLORIDE PRESERVATIVE FREE.
ADLARITY vs EDROPHONIUM CHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Inhibits acetylcholinesterase, prolonging the action of acetylcholine at nicotinic and muscarinic receptors, enhancing neuromuscular transmission.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
2 mg intravenous (IV) or intramuscular (IM) as a test dose; for myasthenia gravis diagnosis: 2 mg IV test dose followed by 8 mg IV after 30 seconds if no reaction; for myasthenic crisis: 2 mg IV; for reversal of nondepolarizing neuromuscular blockade: 0.5-1 mg/kg IV.
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
Terminal elimination half-life is 1-2 hours in healthy adults; prolonged up to 4-6 hours in renal impairment.
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary excretion (10-15%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor